Ibezapolstat

Drug identity checked against registry records

Also recorded as ACX-362E

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile InfectionNCT07513285ACXPPhase 2Recruiting2027-09-29Estimated
ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile InfectionNCT04247542ACXPPhase 2Completed2023-10-03Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.